News
![](https://cdn-uat.mdedge.com/files/s3fs-public/styles/max_width_small/public/images/articles/hemtimes/Kim-Youn-TCLF2017-230.jpg)
Brentuximab vedotin bests standard of care in CTCL
- Author:
- Jen Smith
SAN FRANCISCO—The phase 3 ALCANZA trial is the first to convincingly demonstrate that a new systemic agent can be more effective than standard of...
News
![](https://cdn-uat.mdedge.com/files/s3fs-public/styles/max_width_small/public/images/articles/hemtimes/Garcia-Manero_Guillermo_MD_Credit_MD_Anderson_Cancer_Center_220.jpg)
Combos prove no better than 7+3 for AML
- Author:
- Jen Smith
SAN DIEGO—Neither a 2-drug combination nor a 3-drug combination is superior to 7+3 chemotherapy in younger patients with previously untreated...
News
![](https://cdn-uat.mdedge.com/files/s3fs-public/styles/max_width_small/public/images/articles/hemtimes/prescriptions_Credit_CDC_230.jpg)
Trial supports early treatment of lower-risk ET
- Author:
- Jen Smith
Photo courtesy of CDC SAN DIEGO—Results from the ARETA trial suggest patients with essential thrombocythemia (ET) can benefit from early...
News
![](https://cdn-uat.mdedge.com/files/s3fs-public/styles/max_width_small/public/images/articles/hemtimes/HSCs_being_prepared_for_transplant_credit_Chad_McNeeley_230.jpg)
Study reveals CML patients likely to benefit from HSCT long-term
- Author:
- Jen Smith
Photo by Chad McNeeley SAN DIEGO—New research may help inform the management of patients with chronic myeloid leukemia (CML), according to a...
News
![](https://cdn-uat.mdedge.com/files/s3fs-public/styles/max_width_small/public/images/articles/hemtimes/blood_for_transfusion_Credit_UAB_Hospital_230.jpg)
Restrictive transfusion strategy should be standard after HSCT, doc says
- Author:
- Jen Smith
Photo from UAB Hospital SAN DIEGO—Results of the phase 3 TRIST study support the use of a restrictive red blood cell (RBC) transfusion strategy...
News
![](https://cdn-uat.mdedge.com/files/s3fs-public/styles/max_width_small/public/images/articles/hemtimes/Hydroxyurea_Credit_Zak_Hubbard_230.jpg)
Novel interferon appears safer than HU in PV
- Author:
- Jen Smith
Photo by Zak Hubbard SAN DIEGO—Results of the PROUD-PV trial suggest ropeginterferon alfa-2b is safer than hydroxyurea (HU) for patients with...
News
![](https://cdn-uat.mdedge.com/files/s3fs-public/styles/max_width_small/public/images/articles/hemtimes/AML_in_bone_marrow_240.jpg)
Agent exhibits activity in relapsed/refractory AML
- Author:
- Jen Smith
acute myeloid leukemia SAN DIEGO—A next-generation DNA hypomethylating agent has demonstrated clinical activity and an acceptable safety profile...
News
![](https://cdn-uat.mdedge.com/files/s3fs-public/styles/max_width_small/public/images/articles/hemtimes/ASH2016-outside-Todd-Buchanan-230.jpg)
Drug produces responses in ‘challenging’ patients
- Author:
- Jen Smith
© Todd Buchanan 2016 SAN DIEGO—The oral BCL-2 inhibitor venetoclax can produce high objective response rates (ORRs) in chronic lymphocytic...
News
![](https://cdn-uat.mdedge.com/files/s3fs-public/styles/max_width_small/public/images/articles/hemtimes/mays-jacqueline-NIH-230.jpg)
Rinse could provide short-term treatment of oral cGVHD
- Author:
- Jen Smith
Photo courtesy of NIH SAN DIEGO—Results of a phase 2 study suggest an oral mouth rinse formulation of the steroid clobetasol could provide short-...
News
![](https://cdn-uat.mdedge.com/files/s3fs-public/styles/max_width_small/public/images/articles/hemtimes/ash2016-escalators-JS-230-v2.jpg)
Data suggest one BTK inhibitor could replace another
- Author:
- Jen Smith
ASH Annual Meeting SAN DIEGO—When patients with chronic lymphocytic leukemia (CLL) cannot tolerate one Bruton’s tyrosine kinase (BTK) inhibitor,...
News
![](https://cdn-uat.mdedge.com/files/s3fs-public/styles/max_width_small/public/images/articles/hemtimes/ASH-2016-attendees-JS-230.jpg)
Obinutuzumab bests rituximab in FL study
- Author:
- Jen Smith
ASH Annual Meeting SAN DIEGO—Interim results of the phase 3 GALLIUM trial suggest an obinutuzumab-based treatment regimen provides a progression-...
News
![](https://cdn-uat.mdedge.com/files/s3fs-public/styles/max_width_small/public/images/articles/hemtimes/platzbecker-uwe-240.jpg)
Drug enables transfusion independence in lower-risk MDS
- Author:
- Jen Smith
COPENHAGEN—Results from a pair of phase 2 trials suggest luspatercept can produce erythroid responses and enable transfusion independence in...
News
![](https://cdn-uat.mdedge.com/files/s3fs-public/styles/max_width_small/public/images/articles/hemtimes/richter-johan-240.jpg)
Stopping TKI therapy can be safe, study suggests
- Author:
- Jen Smith
COPENHAGEN—Results of a large study suggest that stopping treatment with tyrosine kinase inhibitors (TKIs) can be safe for patients with chronic...
News
![](https://cdn-uat.mdedge.com/files/s3fs-public/styles/max_width_small/public/images/articles/hemtimes/franco-laura-eha2016-240.jpg)
Site of major bleeding differs with NOACs and VKAs
- Author:
- Jen Smith
COPENHAGEN—Results of a new study suggest that vitamin K antagonists (VKAs) and non-VKA oral anticoagulants (NOACs) can both confer an increased...
News
![](https://cdn-uat.mdedge.com/files/s3fs-public/styles/max_width_small/public/images/articles/hemtimes/eha2016-crowd-aerial-220.jpg)
Platelet transfusion deemed ‘harmful’ in patient group
- Author:
- Jen Smith
Congress of the European Hematology Association COPENHAGEN—Results of the phase 3 PATCH trial suggest that platelet transfusions are not...